Hematopoiesis News Volume 15.06 | Feb 20 2024

    By
    Noshin Noorjahan
    -
    0
    13








    2024-02-20 | HN 15.06


    Hematopoiesis News by STEMCELL Technologies
    Vol. 15.06 – 20 February, 2024
    TOP STORY

    Bone Marrow Plasma Cells Require P2RX4 to Sense Extracellular ATP

    Researchers showed that bone marrow plasma cells use the ligand-gated purinergic ion channel P2RX4 to sense extracellular ATP released by bone marrow osteoblasts through the gap-junction protein pannexin 3.
    [Nature]

    Abstract
    Achieve hassle-free PBMC isolation with SepMate™
    PUBLICATIONSRanked by the impact factor of the journal

    Generation of Complex Bone Marrow Organoids from Human Induced Pluripotent Stem Cells

    Investigators presented a method for generating complex bone marrow-like organoids from human induced pluripotent stem cells.
    [Nature Methods]

    Full Article

    Clonal Hematopoiesis of Indeterminate Potential with Loss of Tet2 Enhances Risk for Atrial Fibrillation through Nlrp3 Inflammasome Activation

    Clonal hematopoiesis of indeterminate potential (CHIP) prevalence was determined in the UK Biobank, and incident atrial fibrillation analysis was stratified by CHIP status and clone size using Cox proportional hazard models.
    [Circulation]

    Abstract

    A Methylation-Phosphorylation Switch Controls EZH2 Stability and Hematopoiesis

    Scientists showed that mouse Kdm1a deletion caused dramatic reduction of polycomb repressive complex 2 (PRC2) proteins, whereas mouse null mutation of L3mbtl3 or Dcaf5 resulted in PRC2 accumulation and increased H3K27 trimethylation.
    [eLife]

    Abstract

    Anti-Leukemic Effect of Azacitidine, a DNA Methyltransferase Inhibitor, on Cell Lines of Myeloid Leukemia Associated with Down Syndrome

    The authors investigated the effects and mechanism of action of azacitidine on three myeloid leukemia associated with Down syndrome cell lines derived from relapsed cases.
    [Experimental Hematology]

    Abstract

    Altered Erythropoiesis via JAK2 and ASXL1 Mutations in Myeloproliferative Neoplasms

    Using primary myeloproliferative neoplasms samples and engineered embryonic stem cells, researchers demonstrated that mutations in JAK2 induce a significant increase in erythroid colony formation, whereas mutations in additional sex combs-like 1 (ASXL1) led to erythroid colony defect.
    [Experimental Hematology]

    AbstractGraphical Abstract

    Safety and Efficacy of Autologous Haematopoietic Stem-Cell Transplantation with Low-Dose Cyclophosphamide Mobilization and Reduced Intensity Conditioning Versus Standard of Care in Refractory Crohn’s Disease (ASTIClite)

    Participants were centrally randomly assigned, 2:1, to either HSCT with a reduced dose of cyclophosphamide (intervention group) or standard care (control group).
    [Lancet Gastroenterology and Hepatology]

    Full Article

    Belantamab Mafodotin, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Part 1 Results of a Phase I/II Study

    The authors investigated the safety and efficacy of belamaf with lenalidomide 25mg on days 1-21 every 28 days and dexamethasone 40mg weekly in transplant ineligible patients with newly diagnosed multiple myeloma.
    [Haematologica]

    Abstract

    Mitapivat Improves Ineffective Erythropoiesis and Iron Overload in Adult Patients with Pyruvate Kinase Deficiency

    Mitapivat’s impact on iron overload and ineffective erythropoiesis was evaluated in adults with pyruvate kinase deficiency who were not regularly transfused in the Phase III ACTIVATE trial and long-term extension.
    [Blood Advances]

    Abstract
    Hassle-free PBMC isolation with SepMate™
    REVIEWS

    Therapeutic Drug Monitoring of Imatinib – How Far Are We in the Leukemia Setting?

    The authors summarize different antileukemic treatment indications for tyrosine kinase inhibitors with focus on imatinib and its pharmacokinetic/-dynamic properties.
    [Expert Review of Clinical Pharmacology]

    Abstract
    INDUSTRY AND POLICY NEWS

    NMDP Announces Enrollment of First Patient in OPTIMIZE Clinical Trial

    NMDPSM announced the enrollment of the first patient in the groundbreaking OPTIMIZE clinical trial. The trial was sponsored by NMDP through the Center for International Blood and Marrow Transplant Research.
    [NMDP (Globe Newswire)]

    Press Release

    Innovative Trials Unveils the Retention Patch Program to Boost Clinical Trial Patient Retention in Pediatric Studies

    A new initiative designed to boost clinical trial patient retention in pediatric studies has been announced by Innovative Trials, global specialists in clinical trial patient recruitment and retention acceleration.
    [Innovative Trials]

    Press Release
    FEATURED EVENT

    AACR Annual Meeting 2024

    April 7 – 10, 2024
    San Diego, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Internship Position – Leukemia Research

    Luxembourg Institute of Health – Strassen, Luxembourg

    Research Associate – Malarial Damage in the Placenta

    University of Alberta – Edmonton, Alberta, Canada

    Department Chair – Cell Biology and Human Anatomy

    UC Davis – Davis, California, United States

    Postdoctoral Scientists – Molecular Basis of Cancer

    Cyprus Cancer Research Institute – Aglandjia, Cyprus

    Research Assistant – Molecular Basis of Cancer

    Cyprus Cancer Research Institute – Aglandjia, Cyprus

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2